tbuckley/cabot-search huggingface dataset:
Rediscovering monoamine oxidase inhibitors.
Journal: BMJ (1989)

be noted.Only with such detailed information will fair comparisons be possible.The real differences in surgical mortality that do exist between surgeons and centres may teach important lessons.One study compared mortality between a teaching hospital and its adjacent district hospital and led to a proper intensive care unit being provided in the district hospital. 14 The confidential inquiry into perioperative deaths emphasised the value of regular reviews of mortality for teaching and training and the importance of organisation.2Some types of surgery should undoubtedly be concentrated in fewer hands.The development of management protocols for procedures with a high mortality and the mandatory participation of senior medical and surgical staff is also inevitable. 15
PROGRESSIVE MELANOSIS OF THE SKIN
Authors: F. RAY BETTLEY
Journal: British Journal of Dermatology (1938)

Journal Article PROGRESSIVE MELANOSIS OF THE SKIN Get access F. RAY BETTLEY, M.D.LOND., M.R.C.P. F. RAY BETTLEY, M.D.LOND., M.R.C.P. Cardiff Royal Infirmary Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology and Syphilis, Volume 50, Issue 4, 1 April 1938, Pages 181–187, https://doi.org/10.1111/j.1365-2133.1938.tb10530.x Published: 01 April 1938
Total Solar Eclipse
Authors: Mary Arneson
Journal: JAMA (1980)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
10. Discovery and development of two novel oncology drugs: BNP and karenitecins
Authors: F Hausheer, K Haridas, D Murali, M Zhao, P Seetharamulu, D Reddy, S Yao, P Pavankumar, J Saxe, H Qiuli, M Wu, N Martinez, A Zukiwski
Journal: Annals of Oncology (1998)
Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger — United States, 2018
Authors: Candice L. Robinson, José R. Romero, Allison Kempe, Cynthia Pellegrini, Peter Szilagyi
Journal: MMWR Morbidity and Mortality Weekly Report (2018)

In October 2017, the Advisory Committee on Immunization Practices (ACIP) approved the Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger - United States, 2018. The 2018 child and adolescent immunization schedule summarizes ACIP recommendations, including several changes from the 2017 immunization schedules, in three figures and footnotes to the figures. These documents can be found on the CDC immunization schedule website (https://www.cdc.gov/vaccines/schedules/index.html). These immunization schedules are approved by ACIP (https://www.cdc.gov/vaccines/acip/index.html), the American Academy of Pediatrics (https://www.aap.org), the American Academy of Family Physicians (https://www.aafp.org), and the American College of Obstetricians and Gynecologists (https://www.acog.org). Health care providers are advised to use the figures and the footnotes together. The full ACIP recommendations for each vaccine, including contraindications and precautions, can be found at https://www.cdc.gov/vaccines/hcp/acip-recs/index.html. Providers should be aware that changes in recommendations for specific vaccines can occur between annual updates to the childhood/adolescent immunization schedules. If errors or omissions are discovered within the child and adolescent schedule, CDC posts revised versions on the CDC immunization schedule website.
Transactions of the Michigan State Medical Society for the Year 1883.
Journal: JAMA (1883)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Management of hypertension. The problem of physician adherence
Authors: M. Moser
Journal: JAMA (1976)

ARTICLES have recently appeared suggesting ways to improve physician compliance or adherence in the management of hypertension, a disease that requires continuous, long-term treatment and that most frequently is asymptomatic.<sup>1-3</sup>Patients with hypertension, unlike those with bursitis, high fever, or prominent symptoms, do not usually seek medical care and may be reluctant to accept care when it is suggested. Various methods have been used and advocated to increase patient adherence to a treatment program: the pill count, home blood pressures, drug detection tests, visiting nurse services, follow-up notices, and others. Some of these have been effective; often they are impractical. Too little attention is still being paid to the role of the physician in terms of his adherence to the management of hypertension. Several statistics stand out in a recent report from the National Heart and Lung Institute. Specifically, a definite increase has occurred in the number of patients
Affiliation Added
Authors: Charles Fuchs, Eli Lilly
Journal: JAMA Oncology (2019)

Trille Kristina Kjaer, PhD; Elisabeth Anne Wreford Andersen, PhD; Jeanette Falck Winther, DMSc; Pernille Envold Bidstrup, PhD; Michael Borre, DMSc; Henrik Møller, DMSc; Signe Benzon Larsen, PhD; Christoffer Johansen, DMSc; Susanne Oksbjerg Dalton, PhD
A New Simplified Acute Physiology Score (SAPS II) Based on a European/North American Multicenter Study
Authors: Jean-Roger Le Gall
Journal: JAMA (1993)

<h3>Objective.</h3> —To develop and validate a new Simplified Acute Physiology Score, the SAPS II, from a large sample of surgical and medical patients, and to provide a method to convert the score to a probability of hospital mortality. <h3>Design and Setting.</h3> —The SAPS II and the probability of hospital mortality were developed and validated using data from consecutive admissions to 137 adult medical and/or surgical intensive care units in 12 countries. <h3>Patients.</h3> —The 13 152 patients were randomly divided into developmental (65%) and validation (35%) samples. Patients younger than 18 years, burn patients, coronary care patients, and cardiac surgery patients were excluded. <h3>Outcome Measure.</h3> —Vital status at hospital discharge. <h3>Results.</h3> —The SAPS II includes only 17 variables: 12 physiology variables, age, type of admission (scheduled surgical, unscheduled surgical, or medical), and three underlying disease variables (acquired immunodeficiency syndrome, metastatic cancer, and hematologic malignancy). Goodness-of-fit tests indicated that the model performed well in the developmental sample and validated well in an independent sample of patients (<i>P</i>=.883 and<i>P</i>=.104 in the developmental and validation samples, respectively). The area under the receiver operating characteristic curve was 0.88 in the developmental sample and 0.86 in the validation sample. <h3>Conclusion.</h3> —The SAPS II, based on a large international sample of patients, provides an estimate of the risk of death without having to specify a primary diagnosis. This is a starting point for future evaluation of the efficiency of intensive care units. (<i>JAMA</i>. 1993;270:2957-2963)
ARTERIO-RENAL DISEASE IN EARLY LIFE.
Journal: JAMA (1900)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
In Vitro Chemical and Cellular Tests Applied to Uranium Trioxide with Different Hydration States
Authors: Eric Ansoborlo, Jacques Chalabreysse, Marie-Helene Henge-Napoli, Eric Pujol
Journal: Environmental Health Perspectives (1992)

A simple and rapid in vitro chemical solubility test applicable to industrial uranium trioxide (UO3) was developed together with two in vitro cellular tests using rat alveolar macrophages maintained either in gas phase or in alginate beads at 37 degrees C. Industrial UO3 was characterized by particle size, X-ray, and IR spectra, and chemical transformation (e.g., aging and hydration of the dust) was also studied. Solvents used for the in vitro chemical solubility study included carbonates, citrates, phosphates, water, Eagle's basal medium, and Gamble's solution (simulated lung fluid), alone, with oxygen, or with superoxide ions. Results, expressed in terms of the half-time of dissolution, according to International Commission on Radiological Protection (ICRP) classification (D,W,Y), varied for different hydration states of UO3, showing a lower solubility of hydrated UO3 in solvents compared to basic UO3 or UO3 heated at 450 degrees C. Two in vitro cellular tests on cultured rat alveolar macrophages (cells maintained in gas phase and cells immobilized in alginate beads) were used on the same UO3 samples and generally showed a lower solution transfer rate in the presence of macrophages than in the culture medium alone. The results of in vitro chemical and cellular tests were compared, with four main conclusions: a good reproducibility of the three tests in Eagle's basal medium the effect of hydration state on solubility, the classification of UO3 in terms of ICRP solubility criteria, and the ability of macrophages to decrease uranium solubility in medium.
Abstract 52: CagA-Positive Exosomes From Patients With Helicobacter Pylori Infection Impair Endothelial Function in Association With Increased Gata-3 Expression
Authors: Xiujuan Xia, Linfang Zhang, Tingzi Hu, Jingshu Chi, Canxia Xu, Zhenguo LIU
Journal: Circulation Research (2017)

A significant link between atherosclerosis and associated cardiovascular diseases especially coronary artery diseases (CAD) and infection with H. pylori (especially CagA-positive) has been established clinically. However, how H. pylori infection leads to atherosclerosis and CAD is unclear. It is well known that endothelial injury and dysfunction plays a critical role in the development of atherosclerosis and CAD. The present study was designed to determine if the effect of cytotoxin associated gene A (CagA) on vascular endothelial cells and related mechanisms. Exosomes were prepared from patients with CagA-positive H. pylori infection and CagA-negative H. pylori infection, and analyzed with electronic microscope and nanoparticle tracking analysis. The presence or absence of CagA in the exosomes from patients was confirmed using Western blot. The exosome preparations were then incubated with human umbilical endothelial cells (HUVEC) for 24 hours. PBS and exosomes from patients without H. pylori infection were used as controls. It was found that the CagA-positive exosomes, not CagA-negative exosomes, significantly inhibited the proliferation of HUVECs and VEGF production in a dose-dependent manner. Incubation with the CagA-positive exosomes, not CagA-negative exosomes, also significantly increased the production of the inflammatory factor CHI3L1 from HUVECs associated with increased expression of GATA-3. The data from the present study demonstrated that CagA-positive exosomes, not CagA-negative exosomes, from patients with H. pylori infection significantly impaired endothelial function in association with increased expression of GATA-3. Further studies are needed to investigate the mechanisms for the action of CagA-positive exosomes on endothelial cells.
OC-072 The Toppic Trial: A Randomised, Double-Blind Parallel Group Trial of Mercaptopurine VS Placebo to Prevent Recurrence of Crohn’s Disease Following Surgical Resection in 240 Patients
Authors: I Arnott, C Mowat, H Ennis, C Keerie, S Lewis, A Cahill, J Morris, M Dunlop, S Bloom, J Lindsay, S Subramanian, J Satsangi
Journal: Gut (2016)

<h3>Introduction</h3> Up to 65% of patients with Crohn’s disease (CD) require an operation to control the disease within the first ten years of the condition. This study assessed whether the use of mercaptopurine (MP) can prevent or delay post-operative recurrence in CD. <h3>Methods</h3> In this randomised, placebo-controlled, double-blind, parallel group trial patients with a confirmed diagnosis of CD undergoing intestinal resection were recruited from 29 UK hospitals. Following informed consent, each patient was randomised to receive a daily oral dose of MP or placebo. Dose was adjusted by weight and thiopurine methyltransferase (TPMT) status and safety monitoring was blinded. Treatment was for a maximum of 36 months. The primary endpoint was defined by clinical recurrence of CD (CDAI &gt; 150 plus 100 point rise) and the need for anti-inflammatory rescue therapy or primary surgical intervention. Secondary endpoints included endoscopic recurrence. <h3>Results</h3> 240 patients (median age 38 years, 60.8% female, 22.9% smokers were enrolled and received at least one dose of study drug. 128 (53%) were randomised to receive MP and 112 (47%) to placebo. No randomised patients were excluded from the analysis. More patients reached primary endpoint within the placebo (n = 26,23.2%) vs MP groups (n = 16,12.5%) with an adjusted p-value of 0.073 (Hazard Ratio (HR) 0.535, 95% CI 0.27–1.06) and an unadjusted p value of 0.046 (HR 0.527, 95% CI 0.28–0.99) Smokers were more likely to reach primary endpoint than non-smokers (p = 0.018 (HR 0.127,95% CI 0.04–0.46 NNT = 3 amongst smokers, HR 0.898, 95% CI 0.42–1.94 NNT = 31 amongst non-smokers). Smoking habit (HR 2.06, 1.09–3.90) but not age at diagnosis, duration of disease, sex, previous surgery or previous thiopurine or anti-TNF exposure predicted primary outcome. A higher proportion of patients on MP compared with placebo maintained complete endoscopic remission (Rutgeerts i0) at weeks 49 (29.7 v 14.4%, p = 0.006), and 157 (22.5% v 12.5%, p = 0.041) on post-hoc analysis. <h3>Conclusion</h3> TOPPIC is the largest, double-blind trial of thiopurines to prevent post-operative recurrence in CD. MP modestly reduces the frequency of clinical post-operative recurrence of CD. This was significant amongst smokers, but not in non-smokers. Adverse events did not differ between groups. <h3>Disclosure of Interest</h3> None Declared
Allergy abstracts
Authors: David Stein Suffern, Harold Friedman, Ohio Monroe, Coleman Stamford, Conn Eugene, Walzer Bridgeport, Berger Freehold, Andre Codispoti Sufern, N Juana, C Glendora, Cal+ Yashmin, Bhassin Middleton, N Robert, Y Lin
Journal: Journal of Allergy and Clinical Immunology (1983)
Software
Authors: Robert Hogan
Journal: JAMA (1990)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Using Magnetic Resonance Direct Thrombus Imaging To Diagnose Deep-Vein Thrombosis in the Lower Legs
Journal: Annals of Internal Medicine (2002)

Summaries for Patients15 January 2002Using Magnetic Resonance Direct Thrombus Imaging To Diagnose Deep-Vein Thrombosis in the Lower LegsSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-136-2-200201150-00001 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail What is the problem and what is known about it so far?Blood clots (thrombi) sometimes form in leg veins (deep-vein thrombosis, or DVT) and can then break free, eventually coming to rest in the blood vessels of the lungs. This problem, called pulmonary embolism, can be fatal. It is important to diagnose DVT rapidly and accurately because treatment with blood thinners is very effective in preventing complications. Some tests for DVT are painful, and they may provide uncertain answers that often require additional tests to be sure of the diagnosis. To measure the reliability of the answers provided by ... Author, Article, and Disclosure InformationAffiliations: The summary below is from the full report titled “Diagnosis of Lower-Limb Deep Venous Thrombosis: A Prospective Blinded Study of Magnetic Resonance Direct Thrombus Imaging.” It is in the 15 January 2002 issue of Annals of Internal Medicine (volume 136, pages 89-98). The authors are DGW Fraser, AR Moody, PS Morgan, AL Martel, and I Davidson.Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoDiagnosis of Lower-Limb Deep Venous Thrombosis: A Prospective Blinded Study of Magnetic Resonance Direct Thrombus Imaging Douglas G.W. Fraser , Alan R. Moody , Paul S. Morgan , Anne L. Martel , and Ian Davidson Metrics 15 January 2002Volume 136, Issue 2Page: I-26KeywordsBloodBlood vesselsDeep vein thrombosisLungsMagnetic resonance imagingProspective studiesPulmonary embolismRadiologistsThrombosisVeins ePublished: 15 January 2002 Issue Published: 15 January 2002 Copyright & PermissionsCopyright © 2002 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Water Lilies
Journal: JAMA (2001)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Computer predictions of abnormal test results. Effects on outpatient testing
Authors: W. M. Tierney
Journal: JAMA (1988)

We developed statistical equations to predict abnormalities on eight commonly ordered diagnostic tests and we gave the predictions to 112 physicians practicing in an academic internal medicine practice. Half of each physician's patients were randomized to intervention status. All diagnostic tests were ordered by microcomputer, and when a physician ordered one of the eight study tests for an intervention patient, the computer displayed the probability (0% to 100%) that the test would be positive for the main abnormality being tested for. The physician could then cancel the test if desired. During a six-month controlled trial, when there were more than 15 000 scheduled patient visits, patient charges for the eight study tests were 8.8% less for the intervention patients. The largest reductions (&gt;10%) were for serum electrolyte level tests and complete blood cell counts, the two most commonly ordered tests. Physicians ordered fewer low-probability tests for intervention patients than for controls, suggesting that with timely predictive information, physicians can target tests to higher-risk patients. (<i>JAMA</i>1988;259:1194-1198)